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OBJECTIVES The aim of the present study was to assess whether anemia is a marker of increased risk during
interventional procedure and poor midterm survival after percutaneous coronary intervention
(PCI).
BACKGROUND Anemia is associated with increased risk of mortality in patients with heart failure and
myocardial infarction (MI).
METHODS We examined the outcomes of 6,116 consecutive PCI patients based on the hemoglobin (Hb)
value before the interventional procedure. Patients were divided into three groups based on
the baseline Hb level (g/l): Hb 10  severe anemia; Hb 10 to 12  mild anemia; Hb 12
 no anemia.
RESULTS The presence of anemia is associated with higher 30-day major adverse cardiac events,
post-PCI peak troponin and creatine kinase-MB fraction, and a longer length of stay. After
controlling for multiple covariates, significant difference in one-year survival was noted in the
anemic groups compared with no anemia group (adjusted hazard ratio for Hb 10 to 12: 1.5
[95% confidence interval 1.3 to 1.8]; for Hb 10: 1.8 [95% confidence interval 1.3 to 2.3];
p 0.004.) This adverse effect of anemia on survival was noted in all three presenting clinical
syndromes (stable angina, unstable angina, and MI).
CONCLUSIONS Anemia is an independent predictor of mortality after PCI and is associated with higher
short-term adverse procedural events. (J Am Coll Cardiol 2004;44:541–6) © 2004 by the
American College of Cardiology FoundationQ
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sn myocardial infarction (MI) (1) and heart failure (2,3),
nemia is known to result in higher mortality. Furthermore,
reoperative anemia is associated with increased periopera-
ive mortality in coronary artery bypass surgery (4). Coro-
ary artery disease patients undergoing percutaneous coro-
ary interventions (PCI) are prone to oxygen demand and
upply mismatch during the procedure, which will be
xaggerated in the presence of anemia. We examined our
nterventional database of PCI patients to determine
hether anemia has a similar impact on PCI patients.
ETHODS
tudy population. We retrospectively analyzed all patients
ndergoing PCI at Mount Sinai Hospital, New York, from
uly 1999 to December 2001 with complete survival data.
urvival data and hemoglobin (Hb)/cardiac enzymes were
vailable in 95% and 100% the patients in the database,
espectively.
ata collection and definitions. One-year follow-up were
rospectively captured and maintained in an institutional
eview board-approved interventional database. All baseline
linical characteristics, procedural details, postprocedural
vents, in-hospital events, 30-day major adverse cardiac
vents (MACE) (death, urgent repeat revascularization,
From the Cardiac Catheterization Laboratory of the Cardiovascular Institute,
ount Sinai Hospital, New York, New York. Dr. Lee was supported by the Canadian
eart and Stroke Foundation/Canadian Institute of Health Research Postdoctoral
ellowship Award. Presented at the 52nd Annual Scientific Session of the American
ollege of Cardiology in March 2003.
Manuscript received December 29, 2003; revised manuscript received March 26,a004, accepted April 13, 2004.-wave MI, and/or creatine kinase-MB fraction [CK-MB]
3  normal if baseline CK-MB normal and non-MI
resentation) were prospectively recorded. Hemoglobin
alue was based on blood draws immediately before the
rocedure. Clinical syndromes (stable angina, unstable an-
ina, MI) were defined as follows: stable angina  anginal
ymptoms with no change in frequency, duration, or inten-
ity of symptoms within four weeks or silent ischemia;
nstable angina  new-onset of angina, accelerated angina,
r rest angina; MIMI occurring within four weeks as per
merican College of Cardiology/European Society of Car-
iology 2000 definition (5). Troponin and CK-MB were
easured serially twice (every 6 to 8 h for the first 24 h) after
he interventional procedures, and the peak values were
ecorded. Mortality data were obtained by telephone follow
all to the private physician and cross-checked by social
ecurity database.
tatistical method. The World Health Organization def-
nition of anemia has different Hb cutoff for anemia (13
g/dl for men and 12 mg/dl for women) (6). We examined
he strength and shape of the relationships of Hb and the
og odds of MACE or death with cubic spline analysis
using SAS macro-based on Molinari et al. [7] and Heinzl
t al. [8]), which demonstrated that the relationship of Hb
nd survival or MACE is not linear. Therefore, we con-
erted Hb from a continuous variable into a categorical
ariable with the threshold values of 10 mg/dl and 12 mg/dl,
ased on the location of the knots in the cubic spline fit. For
implicity of analysis and presentation, we did not perform
separate cubic spine analysis for men and women. Multi-
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Anemia—Mortality Predictor After PCI August 4, 2004:541–6le group comparisons for categorical variables were per-
ormed using Pearson’s chi-square test. Comparisons for
ontinuous variables were performed using analysis of vari-
nce or the Kruskal-Wallis test as appropriate. Kaplan-
eier analysis of mortality data was performed using the
og-rank test both with and without stratification for clinical
yndromes. The proportional hazard assumption for cate-
orical variables was verified using a simplified Kaplan-
eier survival estimate procedure (9); the continuous vari-
ble terms were tested by Cox proportional model
ncorporating interaction of survival time and each individ-
al covariate (10). Because the clinical syndrome variable
xhibits non-proportionality, stratified Cox analysis over
linical syndrome was performed. Hazard ratios for mortal-
ty (adjusted and unadjusted) were obtained using the Cox
roportional hazard model (stratified for clinical syndrome).
djusted odd ratio for 30-day MACE was obtained by
ultiple logistic regressions. Simple two-way analysis of
Abbreviations and Acronyms
CK-MB  creatine kinase-MB fraction
Hb  hemoglobin
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MACE  major adverse cardiac event
MI  myocardial infarction
PCI  percutaneous coronary intervention
Table 1. Baseline Characteristics
Hb >12
(n  4,712)
Male gender (%) 3,567 (76)
Age (yrs) 64.1  11.6
Angina class III–IV (%) 1,602 (34)
Clinical syndromes (%)
Stable angina 1,508 (32)
Unstable angina 2,356 (50)
Acute MI 848 (18)
Diabetes (%) 1,366 (29)
Prior bypass surgery (%) 754 (16)
History of hypertension (%) 3,958 (84)
LVEF (%) 53  11
Prior MI (%) 1,272 (27)
LDL (mmol/l) 2.64  0.85
Multivessel disease (%) 2,686 (57)
GP IIb/IIIa inhibitor use (%) 3,958 (84)
ACC/AHA B2/C lesion (%) 3,910 (83)
Contrast volume (ml) 175  72
Chronic renal failure (%) 211 (4)
NYHA functional class III to IV 147 (6)
Pre-PCI medications (%)
Aspirin 4,382 (93)
ACE inhibitor 2,049 (43)
Beta-blocker 3,307 (69)
Digoxin 276 (6)
Diuretic 956 (20)
Statin 2,977 (62)
ACC  American College of Cardiology; ACE  angiotens
 glycoprotein; Hb  hemoglobin; LDL  low-density
myocardial infarction; NYHA  New York Heart Association; PCaseline variables was performed with SAS/JMP 5.01 (SAS
nstitute Inc., Cary, North Carolina). Logistic and Cox
urvival analysis were performed with SPSS 11.1 (SPSS
nc., Chicago, Illinois). Survival function cubic spline was
erformed with SAS 8.0 (SAS Institute Inc.) utilizing
acro written by Molinari et al. (7). The relationship
etween Hb and MACE was analyzed with SAS/JMP
pline analysis platform. Receiver operating curve analysis
as performed with STATA 8.0 (Stata Corp., College
tation, Texas).
ESULTS
aseline characteristics are summarized in Table 1. The
nemic groups (Hb 10 and Hb  10 to 12) have more
ardiac comorbidities including lower left ventricular (LV)
jection fraction (LVEF) and more multivessel disease.
ther significant differences include higher age, higher
ncidence of diabetes, and hypertension.
There are no differences in angiographic success (p 
.63) or procedural complications (p  0.22) (Table 2).
owever, the anemic groups have higher CK-MB (p 
.04) and troponin I (p 0.0003) after PCI, after excluding
I patients and patients with elevated baseline troponin or
K-MB (Table 2). The total length of stay for the anemic
roups is higher (p 0.001) (Table 2). The 30-day MACE
s higher in the anemic groups (p  0.0002). Because there
re significant differences in baseline characteristics between
Hb  10–12
(n  1,163)
Hb <10
(n  241) p Value
509 (44) 107 (44) 0.0001
69.7  12.0 70.0  12.1 0.0001
430 (37) 75 (31) 0.55
0.0001
337 (29) 55 (23)
582 (50) 135 (56)
244 (21) 51 (21)
535 (46) 125 (52) 0.0001
221 (19) 65 (27) 0.0001
1,058 (91) 219 (91) 0.0001
51  12 47  13 0.0001
337 (29) 77 (32) 0.08
2.46  0.80 2.36  0.88 0.0001
675 (58) 164 (68) 0.0002
907 (78) 171 (71) 0.0001
965 (83) 202 (84) 0.71
168  70 159  78 0.0001
136 (11) 48 (20) 0.0001
82 (12) 14 (10)
1,097 (92) 212 (88) 0.01
609 (51) 129 (53) 0.0001
798 (67) 154 (63) 0.084
105 (9) 40 (16) 0.0001
451 (38) 105 (43) 0.0001
712 (60) 145 (59) 0.28
verting enzyme; AHA  American Heart Association; GP
rotein; LVEF  left ventricular ejection fraction; MI in-con
lipopI  percutaneous coronary intervention.
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August 4, 2004:541–6 Anemia—Mortality Predictor After PCIhe anemic and nonanemic groups, we used multivariate
ogistic regression to control for these variables (Table 3).
he difference in 30-day MACE for the anemia group
emained significant after adjustment.
Post-PCI patients with preprocedure Hb 12 g/l have a
igher one-year survival compared with 10 to 12 g/l group
p  0.0001); while patients in the 10 to 12 g/l group have
igher survival than patients with 10 g/l Hb (p  0.0001)
Table 2, Fig. 1A). The c-statistic for Hb as a predictor for
ne-year mortality is 0.71. To determine whether this
ifference is dependent on the presenting clinical syndromes
stable angina, unstable angina, and MI), we performed a
tratified survival analysis. In all strata, similar survival
ifference is seen among the three Hb subgroups (p 
.005), although, in the stable angina patient group, only
he Hb 12 and Hb 10 groups have statistically different
urvival (p  0.0017) (Figs. 1B to 1D).
Because renal failure is commonly associated with anemia
10), we performed a stratified analysis of the risk of anemia
eparately in patients with or without history of chronic renal
nsufficiency. As shown in Figure 2, anemia is associated with
ncreased mortality in both groups of patients. The risk of
nemia is particularly pronounced in the group with Hb 10
n combination with a history of renal insufficiency, with
ne-year mortality approaching 20%. Furthermore, the mor-
Table 2. Procedural Outcome and Follow-Up
Hb >12
(n  4,712)
Angiographic success (%) 4,571 (97)
Minor procedural events (%) 565 (12)
Elevated CK-MB peak* (%) 333 (14)
Elevated troponin peak* (%) 773 (33)
30-day MACE (%) 57 (1.2)
Total length of stay (days) 2.1  3.7
Death within 1 year (%) 80 (1.7)
*Exclude patients presenting with mycardial infarction, elevat
baseline cardiac enzyme measurements (n  2,379, 545, and
groups, respectively).
MACE  major adverse cardiac events.
able 3. Adjusted 30-Day MACE Odds Ratio and 1-Year Mort
Covariates Adjusted
Odds R
Odds Ratio
onadjusted
Hb 10–12* 1.9
Hb 10* 2.3
xcluded renal failure
Hb 10–12 1.6
Hb 10 2.2
xcluded diabetes and triple-vessel disease
Hb 10–12 1.7
Hb 10 1.8
djusted for first order covariates (multivariate model)†
Hb 10–12 1.8
Hb 10 1.9
Compared with hemoglobin (Hb) 12 group; †Age, diabetes, chronic renal failure, p
merican College of Cardiology/American Heart Association class, multivessel disease,
mount, diuretic use, digoxin use and smoking, glycoprotein IIb/IIIa use, congestive hea
CI  confidence interval; MACE  major adverse cardiac events.ality and MACE risk of anemia is independent of the
resence of renal impairment (Table 3) in our multivariate
odels. Because of the higher incidence of diabetes and
ultivessel disease in the anemia group, we also confirmed the
isk associated with anemia in the nondiabetic PCI patients
ithout triple-vessel disease (Table 3).
To test whether other potential confounding factors com-
letely explain the role of anemia in resulting higher PCI
ortality, Cox proportional hazard model (stratified for clinical
yndromes) was used after we had validated that anemia as a
ortality risk factor fulfills the proportional hazard assump-
ion. After controlling for multiple covariates including LVEF,
ge, diabetes, number of vessels diseased, diuretics, digoxin,
ontrast used, renal failure, and prior MI, anemia (Hb12 vs.
b12) was still a significant predictor of mortality (Table 3).
ISCUSSION
he main finding of the present study is that anemia is
ssociated with higher post-PCI mortality. Both moderate-
evere (Hb 10) and mild anemia (Hb  10 to 12) are
ssociated with increased one-year mortality, while
oderate-severe anemia is associated with higher risk than
ild anemia. Hospital length of stay, post-PCI cardiac
nzymes, and 30-day MACE are higher in patients with
Hb  10–12
(n  1,163)
Hb <10
(n  241) p Value
1,116 (96) 231 (96) 0.63
151 (13) 24 (10) 0.22
93 (17) 22 (21) 0.041
188 (35) 46 (43) 0.0003
40 (3.4) 10 (4.3) 0.0002
3.4  5.3 5.7  9.5 0.001
48 (4.1) 31 (12.8) 0.0001
eline creatine kinase-MB (CK-MB), or troponin or without
or the hemoglobin (Hb) 12, Hb  10–12, and Hb 10
Hazard Ratio for Anemia
for 30-Day MACE Hazard Ratio for 1-Year Mortality
95% CI p Value Hazard Ratio 95% CI p Value
1.3–2.8 1.7 1.5–2.0
1.5–3.1 0.0001 2.5 2.0–3.0 0.0001
1.2–2.8 1.8 1.5–2.1
1.1–5.4 0.003 2.3 1.7–2.9 0.0001
1.0–2.8 2.1 1.6–2.7
1.2–4.1 0.04 2.7 1.7–4.1 0.0005
1.3–3.2 1.5 1.3–1.8
1.2–6.0 0.003 1.8 1.3–2.3 0.004
pass surgery, clinical syndrome, prior myocardial infarction, peripheral vascular disease,
ntricular ejection fraction, percutaneous coronary intervention index artery, sex, contrast
re New York Heart Association III or IV, statin use, beta-blocker use.ed bas
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Anemia—Mortality Predictor After PCI August 4, 2004:541–6nemia. The increased PCI mortality risk associated with
nemia is independent of many baseline risk factors includ-
ng LVEF, diabetes, history of renal failure, multivessel
igure 1. Kaplan-Meier curves for one-year survival of percutaneous co
yndromes. (A) All patients. (B) Stable angina patients (SA). (C) Unstabisease, and history of bypass surgery. (Anemia has been associated with increased mortality in
he presence of significant medical or surgical conditions
uch as MI (1), heart failure (2,3), hematologic malignancy
intervention patients by hemoglobin (Hb) groups stratified by clinical
ina patients (UA). (D) Myocardial infarction patients (MI).ronary
le ang12), renal failure (11,13), vascular surgery (14), and radical
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August 4, 2004:541–6 Anemia—Mortality Predictor After PCIrostatectomy (15). We found that anemia is associated
ith a similar risk in PCI patients: both the short-term and
ong-term outcomes are worse in the anemic patients.
Very recently, Reinecke et al. (16) also noted that anemia
ncreases the mortality after PCI in a smaller study. How-
ver, their study is limited by the small sample size, which
imits the author’s ability to perform statistical adjustment
or confounders and addresses the difference in mortality
etween mild and more severe anemia. Because of our large
ample size, we are able to detect actual progressive increase
n mortality with decreasing Hb. Furthermore, we are able
o enter a large number of covariates in multivariate models
nd to perform stratified analysis to control for various
onfounding factors.
Increased cardiac enzymes after PCI and 30-day MACE
ith anemia is consistent with the hypothesis that ischemia
nduced by balloon inflation during PCI may be less
ell-tolerated because lower Hb results in decreased blood-
xygen carrying capacity and inadequate tissue-oxygen de-
ivery (17). Higher periprocedural myonecrosis might have
ranslated into higher one-year morality in the anemic
atients (18). Measures to decrease oxygen demand in this
etting, such as the use of pre-PCI beta-blockers, may be
articularly beneficial (19).
Anemia contributes to the development of LV hypertro-
hy, mainly via increased cardiac output. Anemia results in
n increase in LV mass, while in others it also results in LV
nd-diastolic volume dilation. These changes increase the
isk of arrhythmias, MI, and myocardial fibrosis (20).
igure 2. Kaplan-Meier curves for one-year survival of percutaneous corona
nsufficiency.Given the recent finding that bone marrow may be a mource of cardiac stem cells and that they are mobilized
uring cardiac injury, endothelial and cardiac stem cell
ecruitment after cardiac injury may be impaired in the
nemic state where the marrow may be dysfunctional
21,22). This is obviously controversial in view of the recent
eport of the failure of hematopoetic stem cell transdiffer-
ntiation into cardiac myocyte in a transgenic mouse model
23).
Incorporation of Hb in risk-stratification scheme will
mprove the performance of risk adjustment algorithms.
one of the major risk prediction instruments (e.g.,
ew York State Percutaneous Transluminal Coronary
ngioplasty Mortality model, American College of
ardiology-National Cardiovascular Data Registry) cur-
ently incorporate anemia in their multivariate models
24,25).
tudy limitations. The major limitations of this study are
he retrospective nature of the analysis and the possibility
hat potentially important risk factors may not be in-
luded in our statistical adjustment, even though we have
djusted 19 risk factors and analyzed the data according
o clinical syndromes. In addition, we do not have the
tiology of anemia of the vast majority of the anemic
atients, and we cannot absolutely rule out the contribu-
ion of the underlying medical disorders to the increased
ortality risk.
onclusions. Our study uncovers an important risk factor
or stratifying PCI patients. Our finding does not prove that
ransfusion for significant anemia pre-PCI will decrease
ervention patients by hemoglobin (Hb) groups stratified by history of renalry intortality, though it is prudent to incorporate the patient’s
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nemia is severe.
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ount Sinai Hospital, Box 1030, One Gustave Levy Place,
ew York, New York 10029-6574. E-mail: samin.sharma@
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